| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
Cholesterol decanoate does not have a defined biological target as it is a biochemical reagent rather than a pharmacologically active drug. As a cholesterol ester, it may interact with cholesterol ester transfer protein (CETP), which mediates the transfer of cholesteryl esters between lipoproteins. It may also be hydrolyzed by cholesterol ester hydrolase to release cholesterol and decanoic acid. The compound's biological effects, if any, would be related to its role as a cholesterol ester in lipid metabolism. However, cholesterol decanoate is primarily used as a research reagent to study cholesterol ester metabolism and lipoprotein function.
|
|---|---|
| ln Vitro |
In vitro, cholesterol decanoate exhibits no pharmacological activity as it is a biochemical reagent. Its utility is demonstrated in studies of cholesterol ester metabolism, lipoprotein function, and lipid biochemistry. The compound can be used as a substrate for cholesterol ester hydrolase or as a standard for lipid analysis. In cell-based assays, cholesterol esters can be taken up by cells via lipoprotein receptors and hydrolyzed to release cholesterol for cellular functions. However, cholesterol decanoate is not used as a therapeutic agent. No specific pharmacological data are available.
|
| ln Vivo |
Cholesterol decanoate is not a pharmacologically active drug and does not exhibit in vivo therapeutic activity. Fatty acid esters of cholesterol constitute about two-thirds of the cholesterol in the plasma, and cholesterol decanoate may be used to study cholesterol ester metabolism and transport. The compound has potential research applications in improving medical conditions such as hypercholesterolemia and inflammation-related diseases, but these are research applications rather than therapeutic uses. The compound is not administered to animals in standard pharmacological studies as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for cholesterol decanoate typically involve cholesterol ester hydrolase or cholesterol ester transfer protein (CETP) studies. A standard protocol for hydrolase assays involves incubating the enzyme with cholesterol decanoate (as a substrate) in the presence of bile salts and phospholipids. Released cholesterol and decanoic acid are measured by enzymatic assays or HPLC. For CETP assays, cholesterol decanoate is incorporated into donor lipoproteins, and transfer to acceptor lipoproteins is measured by radioisotope or fluorescence methods. The compound is also used as a standard for lipid analysis by TLC or HPLC.
|
| Cell Assay |
In vitro cell culture experiments with cholesterol decanoate typically involve macrophage or hepatocyte cell lines to study cholesterol ester accumulation and metabolism. Cells are cultured in appropriate media and treated with cholesterol decanoate incorporated into lipoproteins or cyclodextrin complexes at concentrations ranging from 1-100 µg/mL for 24-72 hours. Cellular cholesterol ester content is measured by enzymatic assays or HPLC. Effects on inflammatory markers (e.g., TNF-α, IL-6) are measured by ELISA. Cell viability is assessed using MTT assays. The compound is also used to study foam cell formation in atherosclerosis research.
|
| Animal Protocol |
In vivo animal studies with cholesterol decanoate are typically conducted in the context of lipid metabolism research. A standard protocol involves administering cholesterol decanoate orally or intraperitoneally to rodents at doses ranging from 10-100 mg/kg. Blood samples are collected for measurement of serum cholesterol, triglycerides, and lipoprotein profiles. Tissues (liver, adipose, aorta) are collected for lipid analysis and histopathological examination. The compound may be used in studies of cholesterol absorption, transport, and metabolism, as well as in models of atherosclerosis. The compound is not used in efficacy studies as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of cholesterol decanoate are related to its behavior as a cholesterol ester. Following oral administration, cholesterol esters are hydrolyzed by pancreatic cholesterol esterase to release cholesterol and free fatty acids, which are absorbed in the intestine. The absorbed cholesterol is re-esterified and incorporated into chylomicrons. Cholesterol esters are distributed in lipoproteins (LDL, HDL) and taken up by tissues via lipoprotein receptors. Cholesterol is metabolized to bile acids or excreted in feces. The pharmacokinetics depend on the lipid formulation and the presence of other dietary fats. Formal pharmacokinetic studies are limited.
|
| Toxicity/Toxicokinetics |
Toxicological data for cholesterol decanoate are limited as it is a research reagent. As a naturally occurring cholesterol ester found in plasma, it is generally considered biocompatible. High doses of cholesterol esters may contribute to hypercholesterolemia and atherosclerosis in susceptible models. The compound should be handled with standard laboratory precautions, including the use of gloves, safety glasses, and working in a fume hood. It should be stored at room temperature in a cool, dark place. No acute toxicity data are available.
|
| Additional Infomation |
CE(10:0) is a cholesterol ester.
Cholesterol decanoate is an ester of cholesterol. Fatty acid esters of cholesterol account for about two-thirds of the cholesterol in blood plasma. Cholesterol is a sterol (a combination of steroids and alcohols) and lipid present in the cell membranes of all body tissues and transported in the blood plasma of all animals. The accumulation of cholesterol esters in the intima of arteries (the innermost layer of arteries, in direct contact with flowing blood) is characteristic of atherosclerosis. Atherosclerosis is a disease affecting the arterial vessels. It is a chronic inflammatory response of the arterial walls, primarily caused by the deposition of lipoproteins (plasma proteins that carry cholesterol and triglycerides). Cholesterol esters are formed by the esterification of cholesterol with long-chain fatty acids; on the one hand, it is the pathway for cholesterol to be transported in the blood via lipoproteins; on the other hand, it is also the pathway for cholesterol itself to accumulate within cells. (A7838). See also: Decanoic acid (note moved to). Cholesterol decanoate is a cholesterol ester used as a biochemical reagent for lipid metabolism research. Fatty acid esters of cholesterol constitute about two-thirds of the cholesterol in the plasma. The compound is formed by the reaction between cholesterol and decanoic acid and has potential research applications in improving conditions such as hypercholesterolemia and inflammation-related diseases. It is also known as cholesteryl decanoate. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is biochemical—serving as a model cholesterol ester for studying lipid metabolism. |
| Molecular Formula |
C37H64O2
|
|---|---|
| Molecular Weight |
540.90
|
| Exact Mass |
540.491
|
| CAS # |
1183-04-6
|
| PubChem CID |
4225619
|
| Appearance |
White to off-white solid powder
|
| Density |
0.96g/cm3
|
| Boiling Point |
110-112°C 0,2mm
|
| Melting Point |
40-42°C
|
| Flash Point |
110-112°C/0.2mm
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.509
|
| LogP |
11.08
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
39
|
| Complexity |
812
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
LJGMGXXCKVFFIS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H64O2/c1-7-8-9-10-11-12-13-17-35(38)39-30-22-24-36(5)29(26-30)18-19-31-33-21-20-32(28(4)16-14-15-27(2)3)37(33,6)25-23-34(31)36/h18,27-28,30-34H,7-17,19-26H2,1-6H3
|
| Chemical Name |
[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] decanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 1 mg/mL (1.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8488 mL | 9.2439 mL | 18.4877 mL | |
| 5 mM | 0.3698 mL | 1.8488 mL | 3.6975 mL | |
| 10 mM | 0.1849 mL | 0.9244 mL | 1.8488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
